Dried blood spots perform well to identify patients with active HCV infection in Vietnam.
hepatitis C virus
sensitivity
specificity
viral load
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
14
11
2019
revised:
20
12
2019
accepted:
06
01
2020
pubmed:
26
1
2020
medline:
10
8
2021
entrez:
26
1
2020
Statut:
ppublish
Résumé
Recently, treatment advances in direct-acting antivirals have radically changed the management of HCV patients. However, in resource-limited countries, identification of patients with active HCV infection is still challenging in remote settings due to the limited access to laboratories able to measure HCV viral load. This study evaluated whether dried blood spots (DBS) transferred to a central laboratory could overcome this challenge. A total of 315 HCV-infected patients, naïve to anti-HCV treatment, provided each three type of samples: plasma, DBS with calibrated quantities of venous blood and DBS with uncalibrated quantities of capillary blood. Qualitative comparison was conducted in terms of detection of HCV viral load on DBS as opposed to plasma to estimate sensitivity and specificity. Quantitative comparisons were conducted by means of correlation estimation. Of the 250 patients with detected plasma HCV viral load, 245 also had detectable DBS HCV viral load (capillary or venous) leading to a sensitivity of 98.0% (95% confidence interval (CI): 95.4%-99.3%); importantly, all measurements with a plasma HCV viral load >118 IU/mL were also detected in DBS. When HCV was not detected in plasma, it was also not detected in DBS resulting in 100% specificity (95% CI: 94.5%-100%). Quantitative HCV viral load results were very similar when utilizing plasma or DBS sample types as illustrated by correlations >0.99. In conclusion, DBS sample types, with either uncalibrated capillary blood or calibrated venous blood, performed well to distinguish patients with active HCV infection, and who therefore need treatment, from other patients.
Substances chimiques
Antiviral Agents
0
RNA, Viral
0
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
514-519Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Organization WH. Global hepatitis report, 2017 (available at: https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/; last accessed: 16 september 2019). 2017.
Ji F, Wei B, Yeo YH, et al. Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia. Aliment Pharmacol Ther. 2018;47(5):550-562.
Luo A, Xu P, Wang J, et al. Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6: A meta-analysis. Medicine (Baltimore). 2019;98(20):e15626.
Berden FA, Aaldering BR, Groenewoud H, IntHout J, Kievit W, Drenth JP. Identification of the best direct-acting antiviral regimen for patients with hepatitis C virus genotype 3 infection: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2017;15(3):349-359.
Thu Thuy PT, Bunchorntavakul C, Tan Dat H, Palecki J, Reddy KR. Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: real-world experience in Vietnam. Antivir Ther. 2018;23(5):415-423.
European Association for the Study of the Liver. Electronic address eee. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66(1):153-194.
Organization WH. Combating hepatitis B and C to reach elimination by 2030 (available at: https://www.who.int/hepatitis/publications/hep-elimination-by-2030-brief/en/; last accessed: September 16, 2019). 2016.
Dokubo EK, Evans J, Winkelman V, et al. Comparison of Hepatitis C Virus RNA and antibody detection in dried blood spots and plasma specimens. J Clin Virol. 2014;59(4):223-227.
Soulier A, Poiteau L, Rosa I, et al. Dried blood spots: a tool to ensure broad access to hepatitis C screening, diagnosis, and treatment monitoring. J Infect Dis. 2016;213(7):1087-1095.
Mahajan S, Choudhary MC, Kumar G, Gupta E. Evaluation of dried blood spot as an alternative sample collection method for hepatitis C virus RNA quantitation and genotyping using a commercial system. Virusdisease. 2018;29(2):141-146.
Santos C, Reis A, Dos Santos CV, et al. The use of real-time PCR to detect hepatitis C virus RNA in dried blood spots from Brazilian patients infected chronically. J Virol Methods. 2012;179(1):17-20.
WHO. Hepatitis data and statistics in the Western Pacific. Available at https://www.who.int/westernpacific/health-topics/hepatitis/regional-hepatitis-data. (last accessed: September 19, 2019). 2018.
Berto A, Day J, Van Vinh CN, et al. Current challenges and possible solutions to improve access to care and treatment for hepatitis C infection in Vietnam: a systematic review. BMC Infect Dis. 2017;17(1):260.
Hajarizadeh B, Grebely J, Applegate T, et al. Dynamics of HCV RNA levels during acute hepatitis C virus infection. J Med Virol. 2014;86(10):1722-1729.
Zaltron S, Spinetti A, Biasi L, Baiguera C, Castelli F. Chronic HCV infection: epidemiological and clinical relevance. BMC Infect Dis. 2012;12(Suppl 2):S2.
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461-511.
Bertisch B, Brezzi M, Negro F, et al. Very low hepatitis C viral loads in treatment-naive persons: do they compromise hepatitis C virus antigen testing? Clin Infect Dis. 2019. [Epub ahead of print].
Sullivan DG, Bruden D, Deubner H, et al. Hepatitis C virus dynamics during natural infection are associated with long-term histological outcome of chronic hepatitis C disease. J Infect Dis. 2007;196(2):239-248.
Aisyah DN, Shallcross L, Hully AJ, O'Brien A, Hayward A. Assessing hepatitis C spontaneous clearance and understanding associated factors-A systematic review and meta-analysis. J Viral Hepat. 2018;25(6):680-698.
Iwamoto M, Calzia A, Dublineau A, et al. Field evaluation of GeneXpert((R)) (Cepheid) HCV performance for RNA quantification in a genotype 1 and 6 predominant patient population in Cambodia. J Viral Hepat. 2019;26(1):38-47.
Llibre A, Shimakawa Y, Mottez E, et al. Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus. Gut. 2018;67(11):2017-2024.
Grebely J, Lamoury FMJ, Hajarizadeh B, et al. Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study. Lancet Gastroenterol Hepatol. 2017;2(7):514-520.
Public reports of WHO prequalified in vitro diagnostics (available at: https://www.who.int/diagnostics_laboratory/evaluations/pq-list/hcv/public_report/en/; last accessed: October 25, 2019).
Saludes V, Folch C, Morales-Carmona A, et al. Community-based screening of hepatitis C with a one-step RNA detection algorithm from dried-blood spots: Analysis of key populations in Barcelona, Spain. J Viral Hepat. 2018;25(3):236-244.